Intech Investment Management LLC Takes Position in Revance Therapeutics, Inc. (NASDAQ:RVNC)

Intech Investment Management LLC purchased a new position in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 44,495 shares of the biopharmaceutical company’s stock, valued at approximately $231,000.

Other hedge funds also recently modified their holdings of the company. Certuity LLC purchased a new position in shares of Revance Therapeutics in the second quarter worth about $26,000. Vanguard Personalized Indexing Management LLC purchased a new position in Revance Therapeutics in the 2nd quarter valued at approximately $33,000. Hsbc Holdings PLC bought a new stake in Revance Therapeutics during the 2nd quarter valued at $38,000. Nisa Investment Advisors LLC lifted its position in shares of Revance Therapeutics by 2,167.5% during the second quarter. Nisa Investment Advisors LLC now owns 18,911 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 18,077 shares in the last quarter. Finally, Creative Planning purchased a new stake in shares of Revance Therapeutics during the third quarter worth $56,000. Institutional investors own 97.70% of the company’s stock.

Revance Therapeutics Trading Down 5.5 %

Shares of RVNC stock opened at $3.94 on Friday. The company’s fifty day moving average price is $4.80 and its 200-day moving average price is $4.45. The stock has a market cap of $413.31 million, a PE ratio of -2.04 and a beta of 0.81. Revance Therapeutics, Inc. has a 12 month low of $2.30 and a 12 month high of $9.74.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The firm had revenue of $59.88 million during the quarter, compared to analysts’ expectations of $67.73 million. On average, sell-side analysts forecast that Revance Therapeutics, Inc. will post -1.54 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on the stock. Barclays reissued an “equal weight” rating and issued a $7.00 price target (down from $10.00) on shares of Revance Therapeutics in a report on Friday, September 13th. StockNews.com assumed coverage on Revance Therapeutics in a research report on Wednesday. They set a “hold” rating for the company. Piper Sandler cut Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 12th. Guggenheim reissued a “neutral” rating on shares of Revance Therapeutics in a report on Monday, August 12th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a research note on Friday, November 8th. Nine equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $9.66.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.